Payment overview · 2025
General Payments
$617.23
46 reported records · 12 companies
Healthcare provider profile · identity verified
Chad Bates, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · KINGSPORT, TN · NPI 1003926353
Verified facts
What the public records show
CMS Open Payments records show Chad Bates, M.D. received $617.23 in general payments during 2025 across 46 reported records.
ABBVIE INC. accounted for 37.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $229.63 | 37.2% | 23 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $173.18 | 28.1% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.36 | 6.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.47 | 5.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.11 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.50 | 3.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.73 | 3.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.46 | 3.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.87 | 2.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.60 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.71 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.61 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $617.23 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $144.01 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $144.01 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.58 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $85.62 | 15 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.85 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.36 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
171 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 870 | 261 |
| Atorvastatin Calcium | Atorvastatin Calcium | 807 | 230 |
| Amlodipine Besylate | Amlodipine Besylate | 794 | 222 |
| Losartan Potassium | Losartan Potassium | 749 | 213 |
| Levothyroxine Sodium | Levothyroxine Sodium | 735 | 195 |
| Omeprazole | Omeprazole | 458 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 431 | 128 |
| Metoprolol Tartrate | Metoprolol Tartrate | 373 | 115 |
| Lisinopril | Lisinopril | 348 | 103 |
| Metformin Hcl Er | Metformin Hcl | 335 | 105 |
| Metformin Hcl | Metformin Hcl | 327 | 93 |
| Gabapentin | Gabapentin | 317 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 304 | 89 |
| Fluticasone Propionate | Fluticasone Propionate | 295 | 123 |
| Tamsulosin Hcl | Tamsulosin Hcl | 295 | 97 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 276 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 246 | 105 |
| Potassium Chloride | Potassium Chloride | 246 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 237 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 225 | 65 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 219 | 65 |
| Furosemide | Furosemide | 218 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 71 |
| Montelukast Sodium | Montelukast Sodium | 216 | 61 |
| Pioglitazone Hcl | Pioglitazone Hcl | 199 | 55 |
| Glimepiride | Glimepiride | 175 | 51 |
| Eliquis | Apixaban | 171 | 39 |
| Meloxicam | Meloxicam | 164 | 59 |
| Trazodone Hcl | Trazodone Hcl | 159 | 53 |
| Finasteride | Finasteride | 156 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 139 | 39 |
| Chlorthalidone | Chlorthalidone | 135 | 35 |
| Famotidine | Famotidine | 135 | 50 |
| Sertraline Hcl | Sertraline Hcl | 132 | 40 |
| Allopurinol | Allopurinol | 126 | 38 |
| Xarelto | Rivaroxaban | 126 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 34 |
| Spironolactone | Spironolactone | 113 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 110 | 41 |
| Tramadol Hcl | Tramadol Hcl | 107 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 98 | 24 |
| Alendronate Sodium | Alendronate Sodium | 96 | 24 |
| Simvastatin | Simvastatin | 96 | 27 |
| Ezetimibe | Ezetimibe | 93 | 27 |
| Mirtazapine | Mirtazapine | 90 | 30 |
| Buspirone Hcl | Buspirone Hcl | 88 | 33 |
| Jardiance | Empagliflozin | 88 | 24 |
| Atenolol | Atenolol | 83 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 17 |
| Ozempic | Semaglutide | 82 | 16 |
| Bupropion Xl | Bupropion Hcl | 81 | 28 |
| Carvedilol | Carvedilol | 81 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 26 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 37 |
| Valacyclovir | Valacyclovir Hcl | 67 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 14 |
| Warfarin Sodium | Warfarin Sodium | 63 | 16 |
| Mounjaro | Tirzepatide | 60 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 12 |
| Donepezil Hcl | Donepezil Hcl | 54 | 19 |
| Clonidine Hcl | Clonidine Hcl | 50 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 14 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 47 | 11 |
| Alprazolam | Alprazolam | 46 | 11 |
| Nitroglycerin | Nitroglycerin | 45 | 34 |
| Prednisone | Prednisone | 45 | 40 |
| Irbesartan | Irbesartan | 43 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 11 |
| Synthroid | Levothyroxine Sodium | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 11 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | 11 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 14 |
| Estradiol | Estradiol | 31 | 11 |
| Fluconazole | Fluconazole | 31 | 22 |
| Ibuprofen | Ibuprofen | 30 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 21 |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Colchicine | Colchicine | 27 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Ibu | Ibuprofen | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 21 |
| Azelastine Hcl | Azelastine Hcl | 24 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 23 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 19 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Eplerenone | Eplerenone | 19 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $617.23 · 46 records | ABBVIE INC. | AREXVY, BREZTRI, BodyGuardian, CAPLYTA, CAPVAXIVE, IBSRELA, KRYSTEXXA, M-M-R II, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VAXNEUVANCE, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error